• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Merck Kgaa (OP: MKGAF )

    161.00 +0.26 (+0.16%)
    Streaming Delayed Price Updated: 3:49 PM EST, Nov 8, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 211
    Open 163.69
    Bid (Size) N/A (0)
    Ask (Size) N/A (0)
    Prev. Close 160.74
    Today's Range 160.60 - 166.20
    52wk Range 144.72 - 200.56
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Week In Review: Eisai Enters $1.5 Billion Molecular Glues Pact With SEED
    Japan’s Eisai Pharma formed a collaboration with SEED, a Pennsylvania biotech, to develop molecular glues for targeted protein degradation of disease-causing proteins. SEED is eligible to receive up to... 
    Via Talk Markets
    Merck Germany's Two Pivotal Trials Flunk In Multiple Sclerosis
    Merck KGaA (OTC: MKGAF) (OTC:  
    Via Benzinga

    Performance

    YTD
    +4.21%
    +4.21%
    1 Month
    -4.73%
    -4.73%
    3 Month
    -11.90%
    -11.90%
    6 Month
    -4.37%
    -4.37%
    1 Year
    -0.87%
    -0.87%

    More News

    Read More
    Week In Review: Hengrui Out-Licenses Next-Gen PARP1 To Merck KGaA For $1.7 Billion
    Via Talk Markets
    Life Sciences Player Repligen's Strategic European Acquisition - What It Means for Investors
    Via Benzinga
    Merck Germany Reports 5% Decline In Q2 Sales, Expects More Decline In 2023
    Via Benzinga
    Novo Nordisk's Obesity Drug Saxenda Not Included In WHO's Essential Drug List
    Via Benzinga
    Abcam Downgrade: Analyst Trims Expectations Amid Activist Investor Engagement and Potential Bid Anticipation
    Via Benzinga
    Roche's Investigational Drug For Relapsing Multiple Sclerosis Reduces Brain Lesions, Data Shows
    Via Benzinga
    Analyst Says Nektar Therapeutics' Rezpeg Prioritization Likely to Spark Investor Questions
    Via Benzinga
    FDA Issues Partial Clinical Hold On Merck Germany's Multiple Sclerosis Study
    Via Benzinga
    Merck Germany Regains Exclusive Global Rights To Cancer Drug From Pfizer
    Via Benzinga
    Incyte Would Now Compete With Merck, Pfizer As Its Skin Cancer Treatment Scores FDA Accelerated Approval
    Via Benzinga
    PDS Biotech, Merck Germany Enter Licensing Pact For Investigational Cancer Treatment
    Via Benzinga
    Mersana Inks Cancer Therapy Development Deal With Merck Germany
    Via Benzinga
    GlaxoSmithKline, Merck KGaA End $4B Cancer Drug Pact
    Via Benzinga
    Nektar, Merck Germany, Pfizer Join Forces For Mid-Stage Bladder Cancer Study
    Via Benzinga
    Merck KGaA Pulls Plug On GSK-Partnered Cancer Drug Trial
    Via Benzinga
    Sutro Biopharma Receives Undisclosed Milestone Payment Under Bispecific ADC Collaboration with Merck
    Via Benzinga
    Immutep, Merck Germany Team Up for Eftilagimod/Bintrafusp Combo Trial In Solid Tumors
    Via Benzinga
    Gene Therapy Player Vera Therapeutics Prices IPO Well Below Range At $11/Share
    Via Benzinga
    Topics Initial Public Offering
    Exposures Securities Market
    UK's NICE Provisionally Rejects Coverage Of Pfizer-Merck KGaA's Bavencio As First-Line Therapy For Bladder Cancer
    Via Benzinga
    Palantir Deepens Relationship With Ringier To Help It Transform Into A Digital-First, Global Media Company
    Via Benzinga
    Novartis Taps Artios In Discovery Pact To Enhance Radioligand Portfolio
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.